Novo Nordisk launched Wegovy HD (semaglutide 7.2 mg) nationwide last week — the highest-dose Wegovy injection to date. In the STEP UP trial (Wharton et al., Lancet Diabetes Endocrinol, 2025), patients on the 7.2 mg dose lost an average of 20.7% of their body weight over 72 weeks, compared to 17.5% on the existing 2.4 mg dose.
For employers, the clinical news is straightforward: a more effective dose option now exists. The more interesting development is how Novo is distributing it — and what that signals about where the GLP-1 market is headed.
The DTC Channel Is Now Real
Days before the Wegovy HD launch, Novo announced a multi-month subscription program for Wegovy through telehealth providers including Ro, WeightWatchers, LifeMD, Hims & Hers, and Sesame. The pricing:
- Wegovy injection (up to 2.4 mg): $249–$329/month depending on subscription length
- Wegovy HD (7.2 mg): $399/month through NovoCare Pharmacy and telehealth providers
- Wegovy pill: $149/month for lower doses
These are self-pay prices — no insurance required. Patients access the drug through telehealth prescribers and Novo's own pharmacy, bypassing PBMs and employer benefits entirely.
This isn't a side channel. Novo is building a parallel distribution system. When a manufacturer launches subscription pricing through consumer telehealth platforms with its own branded pharmacy, it's creating a direct relationship with patients that doesn't depend on employer coverage decisions.
Why This Matters for Employer Plan Design
For benefits leaders, the DTC channel creates three practical dynamics to prepare for:
Utilization becomes less visible. When employees fill GLP-1 prescriptions through their employer plan, the claims data shows up in pharmacy reporting. When they buy directly through a telehealth subscription at $249–$399/month, the employer sees nothing. That matters for population health management — you can't manage what you can't measure. Employers who rely on claims data to understand their population's GLP-1 utilization may be undercounting.
The copay comparison shifts. For employees with high-deductible plans, the DTC cash price may be lower than their out-of-pocket cost through insurance — especially early in the plan year before deductibles are met. An employee facing a $2,000 deductible and then 20% coinsurance on a $1,300/month drug may find $249/month through a telehealth subscription more attractive than going through their benefits. This self-selection away from the plan has implications for risk pools and cost projections.
Dose escalation creates a new formulary question. Wegovy HD at 7.2 mg is positioned for patients who've tolerated 2.4 mg for at least four weeks and need additional weight reduction. From a plan design perspective: if 2.4 mg achieves 17.5% weight loss and 7.2 mg achieves 20.7%, does the incremental 3.2 percentage points justify the higher cost? At $399/month versus the standard dose pricing, the cost-per-additional-percentage-point of weight loss may actually worsen at higher doses. Employers covering GLP-1s will need dose escalation criteria in their prior authorization protocols — or risk an upward drift in per-member pharmacy spend as prescribers move patients to the highest available dose by default.
The Subscription Model's Broader Signal
Novo's subscription pricing — $249/month on a 12-month commitment for the standard injection — is a deliberate move toward predictable, consumer-facing economics. It mirrors the shift we've already seen with Foundayo's $149/month starting price and the Medicare GLP-1 Bridge at $50/month.
The pattern: GLP-1 manufacturers are building multiple access pathways — employer coverage, DTC subscriptions, Medicare programs — that operate in parallel. Employees will choose whichever pathway offers the best combination of cost, convenience, and speed.
For employer plan design, this means coverage decisions are no longer the only lever controlling GLP-1 utilization. An employer that drops GLP-1 coverage isn't preventing employees from accessing the drugs — they're pushing employees to the DTC channel where the employer has no visibility, no data, and no ability to pair coverage with a maintenance strategy.
What Benefits Leaders Should Do Now
Review your dose escalation criteria. If your plan covers Wegovy, your PBM will need updated prior authorization criteria for the 7.2 mg dose. Without it, you'll see cost creep as prescribers move patients up to the highest available formulation.
Model the DTC leakage. Work with your PBM and data analytics team to estimate how many employees might shift to self-pay. Look at your high-deductible plan population and GLP-1 utilization data. If there's a segment where DTC pricing undercuts the employee's out-of-pocket cost, some will migrate — and your claims data will understate actual utilization.
Reconsider the coverage question. If your plan doesn't cover GLP-1s for weight loss, the DTC channel means your employees may be accessing them anyway — without your knowledge, without a maintenance program, and without any benefit to your population health data. Covering GLP-1s with appropriate guardrails and a behavioral component may give you more visibility and more influence over outcomes than not covering them.
The GLP-1 distribution landscape is fragmenting. Employer coverage is becoming one channel among several, not the gatekeeper. The employers who navigate this well will be the ones who design their benefits to compete with — not ignore — the DTC alternatives.
